Drugs / BPL-1357
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05027932 | Jun 2022 → Jun 2023 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07215858 | Jul 2026 → Mar 2028 expected | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPL-1357 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215858 ↗ |
| Modality | Vaccine | “BPL-inactivated, whole-virus, universal influenza vaccine” NCT05027932 ↗ |
| Route | Intramuscular | “It is administered either IM or IN depending on the assigned treatment group.” NCT05027932 ↗ |
| Route | Intranasal | “It is administered either IM or IN depending on the assigned treatment group.” NCT05027932 ↗ |